Original Article
Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile Dysfunction
N Engl J Med 1996; 334:873-877April 4, 1996
- Abstract
Background
Erectile dysfunction is a common medical problem affecting many men. Although several intracavernosal therapies are available, their efficacy and safety have not been studied systematically.
Methods
We investigated the efficacy and safety of alprostadil formulated for intracavernosal treatment in three separate multi-institutional, prospective studies in men with erectile dysfunction of vasculogenic, neurogenic, psychogenic, and mixed causes. Clinical and laboratory evaluations of erection and the feasibility and satisfactoriness of sexual activity as assessed both by the men and by their partners were the primary measures of efficacy.
Results
In a dose–response study of 296 men, all doses of alprostadil were superior to placebo and there was a significant dose–response relation (P<0.001), resulting in higher response rates with increasing doses of alprostadil (from 2.5 to 20 μg). In a dose-finding study of 201 men, the minimal effective dose was <2 μg in 23, 20, 38, and 23 percent of men with erectile dysfunction of neurogenic, vasculogenic, psychogenic, or mixed causes, respectively. In a six-month self-injection study in 683 men, the participants reported being able to have sexual activity after 94 percent of the injections. The men and their partners rated the sexual activity as satisfactory after 87 and 86 percent of the injections, respectively. Penile pain, usually mild, occurred in 50 percent of the men at some time but after only 11 percent of the injections. Prolonged erections occurred in 5 percent of the men, priapism in 1 percent, penile fibrotic complications in 2 percent, and hematoma or ecchymosis in 8 percent.
Conclusions
In men with erectile dysfunction, intracavernosal injection of alprostadil is an effective therapy with tolerable side effects.
Media in This Article
Figure 3
Distribution of Initial and Final Doses of Alprostadil in 577 Men with Erectile Dysfunction in the Study of Efficacy and Safety, According to Dose Category.Figure 1
Percentages of 296 Men with Erectile Responses to Single Injections of Placebo or Alprostadil as Evaluated Clinically (“Full Rigidity”) and by RigiScan (≥70 Percent Rigidity for ≥10 Minutes).Article Activity
- Article
Erectile dysfunction, the consistent inability to attain and maintain a penile erection sufficient to permit satisfactory sexual intercourse, may affect 20 million to 30 million American men.1,2 It impairs men's mental well-being and interactions with their family and associates. Most men with erectile dysfunction are thought to have organic impairment,3 especially circulatory insufficiency, with psychological problems as important contributing factors. The available treatments include psychological and medical therapy, vacuum constriction devices, drug therapies involving intracavernosal self-injection, microvascular arterial or venous surgery, and penile-prosthesis implantation.3 With self-injection therapies, a man can treat himself after the desirable dose of the drug is selected by his physician and he has been instructed in the self-injection technique.4
Intracavernosal-injection therapy is an important therapeutic option for men with erectile dysfunction of various causes. It does not involve surgery or devices and has reproducible erection responses and tolerable side effects. Physiologic mechanisms that relax penile smooth muscle and elicit erections are mimicked by vasoactive drugs administered intracavernosally that directly relax the smooth muscle.5,6 Published reports on the intracavernosal use of alprostadil since 19867,8 consist primarily of data derived from uncontrolled, retrospective studies with different formulations. Although these data indicate the efficacy and safety of alprostadil for the treatment of erectile dysfunction,9,10 they have not usually been based on investigational designs that meet strict standards. Accordingly, we conducted three prospective studies, each in a separate group of impotent men, to address the issues of effective dosing, efficacy, responses of patients and their partners, and the safety of a new formulation of alprostadil sterile powder (Caverject) for intracavernosal injection.
Methods
We conducted the three studies at 51 sites throughout the United States. The protocols were approved by the institutional review boards, and all participants gave written informed consent. Men with erectile dysfunction of vasculogenic, neurogenic, psychogenic, or mixed origin lasting at least four months who were seen in urology clinics at these sites were enrolled. Screening procedures consisted of medical histories and physical examinations, including testing for the bulbocavernous reflex. The presence of this reflex suggests an intact sacral arc. Laboratory evaluation included a complete blood count, serum biochemical tests, and urinalysis. Men were excluded from the study if they had penile deformities (including fibrosis), a history of priapism, the sickle-cell trait, recent major illness, uncontrolled diabetes mellitus or hypertension, a major psychiatric disorder, infection with the human immunodeficiency virus, or other transmittable disease. Heavy smokers (>40 cigarettes per day) were also excluded. Serum testosterone (in the morning), prolactin, free thyroxine, and thyrotropin were measured to rule out endocrine causes of erectile dysfunction.
Alprostadil was supplied as a sterile, freeze-dried powder in a 5-ml vial. After it was reconstituted with 1 ml of bacteriostatic water, each vial contained 20 μg of alprostadil, 173 mg per milliliter of lactose, and 47 μg per milliliter of sodium citrate. The placebo contained lactose and sodium citrate and had the same appearance.
Only one person (either an investigator or a research nurse) gave the injections at each center. The penis was pulled away from the body until the skin was taut. A syringe with a 27- to 30-gauge 1/2-inch needle was held at a right angle to the penis, and the injection was given at the base of the penis on either side, avoiding visible veins. Pressure was applied to the injection site for five minutes or until bleeding stopped.
The same person who gave the injection palpated the penis and rated the rigidity as absent, partial, or full at specified times after the injection; full rigidity implied an erection sufficient for intercourse. In the first two studies, radial rigidity was measured by the RigiScan Ambulatory Rigidity and Tumescence System3 (Dacomed, Minneapolis) before injection and for two hours afterward. The RigiScan was attached to a personal computer during monitoring and used special software developed for this project. A response was defined as >70 percent rigidity at the tip or the base of the penis lasting 10 consecutive minutes or longer. The duration of erection was also measured. Prolonged erection was defined clinically as an erection lasting from four to six hours, and priapism as an erection lasting more than six hours. Statistical evaluations were based on an intention-to-treat analysis including all the men who entered the study and received at least one dose of drug or placebo.
Dose–Response Study
In this parallel-design, double-blind study, fixed doses of alprostadil or placebo were administered. A total of 296 men, 21 to 74 years old (mean, 54), were enrolled at 14 sites, with 9 to 40 men enrolled per site. The cause of erectile dysfunction in these men was determined on the basis of the medical history, physical examination, and laboratory evaluation. The men were randomly assigned to one of five groups and received a single 1.0-ml injection of either placebo (59 men) or alprostadil in doses of 2.5 μg (57 men), 5 μg (60 men), 10 μg (62 men), or 20 μg (58 men). Both the person who gave the injection and the patient were unaware of what was given.
Dose-Finding Study
This single-blind dose-escalation study was conducted at 15 sites with a total of 201 men (including 12 who had participated in the dose–response study) who were 20 to 72 years of age (mean, 54); 5 to 30 men were enrolled per site. In these men, the diagnosis of erectile dysfunction was made on the basis of medical history, physical examination, laboratory evaluation, duplex or color Doppler sonography, penile–brachial index (penile systolic pressure divided by brachial systolic pressure), and penile biothesiometry.3,4 The diagnosis of psychogenic erectile dysfunction was based on the history and the exclusion of other causes. The initial dose of alprostadil was 0.5 μg, followed by 1, 2, 3, 4, 5, 7.5, 10, 15, 20, 25, and 30 μg at intervals of 2 to 14 days, until a minimal effective dose (resulting in >70 percent rigidity for >10 minutes by RigiScan testing) was established or the maximal dose of 30 μg was reached.
Study of Efficacy and Safety
This open-label, flexible-dose study in 683 men (including 40 who had participated in the dose–response study) 20 to 79 years of age (mean, 58) with stable sexual relationships was undertaken at 33 sites to investigate the safety and efficacy of alprostadil and the feasibility of self-injection at home. Three to 61 men were enrolled per site. The cause of erectile dysfunction in these men was assessed by history taking, physical examination, and laboratory evaluation. Penile ultrasonography was performed to rule out preexisting fibrosis of the corpora cavernosa. The optimal dose of alprostadil, defined as the dose inducing an erection sufficient for vaginal penetration and lasting <60 minutes, was established for each man by titration. The men were trained to inject themselves before beginning the six-month trial, during which they recorded in diaries the frequency of drug use as well as evaluations of the erection (none, partial, full) and of intercourse after each injection. The sexual activity after each injection was rated by the men and their partners as satisfactory or unsatisfactory. The partners also had the option of not rating satisfaction. During monthly clinic visits, the data from the diaries were transferred to the case-report form, and open-ended questions were asked to elicit information about adverse medical reactions. If necessary, the dose of alprostadil was adjusted by the investigator during the study. Physical examination and laboratory evaluation were repeated at the end of the study.
Statistical Analysis
For the categorical variables in the dose–response study (erection response to injection, based on clinical and RigiScan evaluations), the extended Mantel–Haenszel test11 was used to assess the overall dose effect. Pairwise comparisons of alprostadil doses with placebo were performed with the use of the Mantel–Haenszel test. The overall dose–response relation among alprostadil doses was determined with logistic-regression analysis. The duration of erection was analyzed by analysis of variance, with pairwise comparisons performed within the analysis-of-variance model. Adjustment was made for multiple testing by the requirement that the overall test results be significant before pairwise comparisons were considered.
When the minimal effective dose or optimal dose was calculated (in the dose-finding and the efficacy and safety studies), the data on men who did not respond were included in the calculations and treated as censored observations.
Results
Dose–Response Study
Of the 296 men, 130 (44 percent) were judged to have a vasculogenic cause of erectile dysfunction, 41 (14 percent) to have a psychogenic cause, 39 (13 percent) to have a neurogenic cause, and 86 (29 percent) to have mixed causes. Only seven men (2 percent) had received previous intracavernosal treatment. All the men completed the study. Figure 1Figure 1
Percentages of 296 Men with Erectile Responses to Single Injections of Placebo or Alprostadil as Evaluated Clinically (“Full Rigidity”) and by RigiScan (≥70 Percent Rigidity for ≥10 Minutes). shows the percentage of men who responded to each dose of alprostadil. No man responded to placebo. The differences in the response rates in both the clinical and the RigiScan evaluations between each of the doses of alprostadil and placebo were statistically significant (P<0.01 or P<0.001). There was also a statistically significant dose–response relation, with higher clinical response rates (P<0.001) and higher RigiScan response rates (P = 0.005, except with the 10-μg dose) with increasing doses of alprostadil.The mean duration of erection after alprostadil injection ranged from 12 minutes after the 2.5-μg dose to 44 minutes after the 20-μg dose (Figure 2Figure 2
Relation between Alprostadil Doses and the Mean (±SE) Duration of Erection as Measured by RigiScan (≥70 Percent Rigidity for ≥10 Minutes) in 296 Men with Erectile Dysfunction.), and the relation was linear (P = 0.025). Penile pain was reported by 54 of the 237 men (23 percent) who received alprostadil, but the pain was not related to the dose. Priapism developed in one man after he received 5 μg; it was treated with blood aspiration and irrigation with ephedrine. Five men reported prolonged erections, but only in two of them did the erection last four hours or more. One man had received 5 μg of alprostadil, two 10 μg, and two 20 μg.Dose-Finding Study
Of the 201 men in this study, 73 (36 percent) had a vasculogenic cause of erectile dysfunction, 48 (24 percent) had a neurogenic cause, 33 (16 percent) had a psychogenic cause, and 47 (23 percent) had mixed causes. None had been treated before with intracavernosal therapy. A total of 135 men completed the study. The reasons for discontinuation were protocol violation (3 men), nonserious medical events (4), loss to follow-up (14), misinterpretation of RigiScan data (32), and premature termination of study (13). Among the men who completed the study, the minimal effective dose (resulting in >70 percent rigidity for >10 minutes) was <2 μg in 9 of 24 (38 percent), 7 of 31 (23 percent), 10 of 50 (20 percent), and 7 of 30 (23 percent) men with erectile dysfunction of psychogenic, neurogenic, vasculogenic, and mixed causes, respectively. Eleven men responded to the lowest alprostadil dose tested (0.5 μg). The median effective dose was 3.0, 4.0, and 5.0 μg in the psychogenic, neurogenic, and vasculogenic groups, respectively, and 4.5 μg in the mixed group. The duration of the erection was 11 to 100 minutes (mean, 37). Penile pain occurred in 69 of the 201 men (34 percent), 2 of whom refused further treatment. However, only 148 of all 1382 injections (11 percent) caused pain. No man had prolonged erection or priapism.
Study of Efficacy and Safety
Of the 683 men in this study, 389 (57 percent), 92 (13 percent), 67 (10 percent), and 135 (20 percent) were judged to have vasculogenic, neurogenic, psychogenic, and mixed causes of erectile dysfunction, respectively. Thirty-nine percent of these men had received intracavernosal treatment previously. Adequate doses of alprostadil (between 0.2 and 80 μg) were determined in the clinic for 606 (89 percent) of the 683 men. These doses were between 7.5 and 20 μg for 364 (60 percent) and <20 μg for 475 (78 percent). Of the 606 men, 577 began treatment with the drug at home by self-injection (29 chose not to begin home treatment). Four hundred seventy-one (69 percent) completed the six-month study. The reasons for discontinuation were nonserious adverse reactions, most often penile pain (in 64 men), lack of efficacy (56), loss to follow-up (27), dislike of self-injection (19), violation of the protocol (14), difficulty in scheduling visits (10), problems with partners (8), no need for the drug (5), difficulty with injection technique (4), intercurrent illness (3), lack of sex drive (1), and death (1, unrelated to the study drug).
The initial adequate dose was continued by 247 (43 percent) of the 577 men who began self-treatment at home; the dose was increased for 231 (40 percent) and reduced for 99 (17 percent) during the six months of therapy. The mean dose was 20.7 μg at the end of the study, as compared with 17.7 μg at the start. The distribution of initial and final doses is shown in Figure 3Figure 3
Distribution of Initial and Final Doses of Alprostadil in 577 Men with Erectile Dysfunction in the Study of Efficacy and Safety, According to Dose Category..Of the 13,762 alprostadil injections after which sexual activity was recorded, 11,924 (87 percent) resulted in satisfactory sexual activity. According to the partners, satisfactory intercourse resulted from 8496 of 9892 injections (86 percent) (Table 1Table 1
Assessment by the Men and Their Partners of Sexual Activity after Self-Injection with Alprostadil at Home in the Study of Efficacy and Safety.).Penile pain was reported by 343 of the 683 men (50 percent) (Table 2Table 2
Frequency of Local Medical Events among 683 Men Treated with Alprostadil in the Study of Efficacy and Safety.), but pain occurred after only 1873 of all 16,575 injections (11 percent), indicating that many men had pain after only some injections. In most instances, the pain was mild, but 43 men (6 percent) withdrew from the study because of pain. Prolonged erection was reported by 35 men (5 percent), of whom 3 discontinued treatment. Priapism occurred in five men (1 percent) after doses of 5 to 12 μg; only one man required drug therapy, and none discontinued treatment. Penile fibrosis (including Peyronie's disease, deviation or curvature, and nodules) was detected in 15 men (2 percent) during the study.Systemic medical events possibly related to alprostadil occurred in 39 men (6 percent). Most of these events affected the urogenital system (e.g., testicular pain and swelling; scrotal pain and edema; decreased or increased urinary frequency; hematuria; and pelvic pain). None were considered serious. One man died of cardiac arrest judged to be unrelated to alprostadil. Only nine men (1 percent) reported side effects potentially related to hypotension, such as irregular pulse, lightheadedness, dizziness, diaphoresis, vasodilation, and vasovagal reaction. Results of laboratory tests revealed no evidence of alprostadil-induced abnormalities.
Discussion
The in-office erection response in the first two studies was assessed by objective, computerized RigiScan technology for measuring penile rigidity. The selected RigiScan response was based on a nocturnal penile-tumescence study, in which a rigidity of >70 percent was considered sufficient for intercourse and a rigidity of 40 to 70 percent was considered only partially sufficient.12 Our criteria for response were more conservative than those used in another recent study of intracavernosal therapy.13
In the dose–response study, placebo failed to induce a clinical or RigiScan response. This confirms the results of a crossover study of alprostadil in men with psychogenic impotence.14 Alprostadil was increasingly effective as doses increased from 2.5 to 20 μg. A dose–response relation was also found in another trial of alprostadil by von Heyden et al.15 The lower response rates in our trial, as compared with earlier studies of alprostadil,16,17 may have resulted from our use of a random, single injection of alprostadil at fixed doses, not arrived at by titration; our liberal entry criteria; and the administration of injections in the doctor's office.
Although men with neurogenic erectile dysfunction were reported to respond to alprostadil with increased sensitivity,18 men with vasculogenic dysfunction responded less well.19 In the dose-finding study, a similar percentage of men in each of these two groups responded to a dose of 2 μg of alprostadil or less, although the median effective dose was higher in the vasculogenic group. It is possible that men with milder vasculogenic dysfunction responded to the dose of 2 μg or less.
The results of all three studies indicate the need for the individualization of optimal doses of alprostadil, which should be established by dose titration in the physician's office, starting with a low dose. We recommend an initial dose of 2 to 3 μg, followed by small increments. Doses self-injected during home therapy should be adjusted as needed.
The results of the study of efficacy and safety reflected the expected use of alprostadil in real-life situations. The rate of dropout for therapy-related reasons was lower than that reported elsewhere,18 possibly because of the close monitoring and because of the free drug supply. With respect to the most important clinical end point — satisfaction with sexual activity — a high percentage of both the men and their partners were satisfied with alprostadil treatment. The side effects were similar to those reported in studies using different formulations of alprostadil.16,17 Penile pain was the principal side effect; its frequency was highest in the study of efficacy and safety. Though it was rated mostly as mild, it was a limiting factor for some men. Pain is probably induced by alprostadil itself, since prostaglandins of the E group have a pain-sensitizing action.20 Comparison of the frequency of prolonged erection or priapism after the administration of alprostadil with the frequency in studies of other vasoactive drugs is difficult because of different definitions of these events and different doses. Nevertheless, in a review of eight large studies,21 11 percent of men treated with papaverine had prolonged erections (lasting three to six hours). Clinicians who prescribe self-injection therapy with vasoactive drugs must inform men of the potential seriousness of priapism and the need to seek prompt treatment if it occurs.
Penile fibrosis was observed in the study of alprostadil's efficacy and safety. However, it also occurs without intracavernosal therapy,22 appears to be more common in men with erectile failure,23 and has also been reported after injections of other vasoactive drugs.21,24,25 Repeated needle injury26 and chronic microtrauma induced by sexual activity, especially with a partially erect penis, may be other contributing factors. Proper training of men in the injection technique may minimize the risk of this complication. Men who are treated with alprostadil should be instructed to report any new side effects related to the penis and should be supervised periodically during self-injection. If penile fibrosis is detected, the treatment should be discontinued.
In conclusion, intracavernosal alprostadil is an effective and safe therapy for men with erectile dysfunction, provided the individual dose is established by titration and the men are trained in the injection technique and are supervised periodically during self-injection.
Supported by grants from the Upjohn Company. Both authors are employees of the Upjohn Company.
We are indebted to Dr. Irwin Goldstein for valuable help in the preparation of this manuscript and to Ms. Cindy L. Shattuck for technical assistance.
Source Information
From the Clinical Development Unit, the Upjohn Company, Kalamazoo, Mich.
Address reprint requests to Dr. Linet at the Upjohn Company, 7000 Portage Rd., Kalamazoo, MI 49001-0199.
The members of the Alprostadil Study Group are listed in the Appendix.
Appendix
The members of the Alprostadil Study Group are as follows: A.M. Alabaster, Memphis, Tenn.; S.M. Auerbach, Newport Beach, Calif.; J. Bennett, Atlanta; R.E. Berger, Seattle; C.B. Brendler, Baltimore; J. Boullier, St. Louis; S.A. Brosman, Santa Monica, Calif.; J. Buch, Farmington, Conn.; T.A. Burns, Olathe, Kans.; S. Childs, Alabaster, Ala.; R.V. Clark, Durham, N.C.; M.J. Duckett, Baltimore; J.F. Eid, New York; I. Fishman, Houston; W. Fitch III, San Antonio, Tex.; J.E. Fowler, Jackson, Miss.; H.A. Fuselier, Jr., New Orleans; I. Goldstein, Boston; J. Gonzalez, Royal Oak, Mich.; J.R. Goodman, Gretna, La.; G.B. Hodge, Jr., Orlando, Fla.; L.L. Keeler, Cherry Hill, N.J.; L.D. Knoll, Nashville; R.W. Lewis, Rochester, Minn.; D.B. Lillie, Kenmore, N.Y.; L.K. Lloyd, Birmingham, Ala; T.F. Lue, San Francisco; K.F. McVary, Chicago; H.D. Mitcheson, Brighton, Mass.; T. Mulligan, Richmond, Va.; M.I. Murdock, Greenbelt, Md.; P.W. Nadig, San Antonio, Tex.; K. Ng, Miami; M.P. O'Leary, Boston; H. Padma-Nathan, Los Angeles; A.L. Patterson, Memphis, Tenn.; W.M. Patterson, Birmingham, Ala.; J.J. Prendergast, Atherton, Calif.; C.F. Reid, Winston-Salem, N.C.; J.B. Roy, Oklahoma City; W.M. Schiff, Fresno, Calif.; A. Seftel, Cleveland; R. Shabsigh, New York; J.P. Spirnak, Cleveland; J.F. Stecker, Norfolk, Va.; G. Steinberg, New Brunswick, N.J.; J.A. Stone, Cumberland, Md.; J. Susset, Providence, R.I.; S. Weiner, Boulder, Colo.; C.F. White, Mobile, Ala.; and H.A. Wise II, Columbus, Ohio.
- References
References
1
NIH Consensus Development Panel on Impotence
CrossRef | Web of Science2
Feldman HA ,Goldstein I ,Hatzichristou DG ,Krane RJ ,McKinley JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
Web of Science | Medline3
Krane RJ ,Goldstein I ,Saenz de Tejada I . Impotence. N Engl J Med 1989;321:1648-1659
Full Text | Web of Science | Medline4
Lue TF . Intracavernous drug administration: its role in diagnosis and treatment of impotence. Semin Urol 1990;8:100-106
Medline5
Kim N ,Azadzoi KM ,Goldstein I ,de Tejada IS . A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991;88:112-118
CrossRef | Web of Science | Medline6
Rajfer J ,Aronson WJ ,Bush PA ,Dorey FJ ,Ignarro LJ . Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-94
Full Text | Web of Science | Medline7
Ishii N ,Watanabe H ,Irisawa C , et al. Studies on male sexual impotence. Report 18. Therapeutic trial with prostaglandin E1 for organic impotence. Nippon Hinyokika Gakkai Zasshi 1986;77:954-962
Medline8
Virag R ,Adaikan PG . Effects of prostaglandin E1 on penile erection and erectile failure. J Urol 1987;137:1010-1010
Web of Science | Medline9
Stackl W ,Hasun R ,Marberger M . Intracavernous injection of prostaglandin E1 in impotent men. J Urol 1988;140:66-68
Web of Science | Medline10
Porst H . Prostaglandin E1 bei erektiler Dysfunktion. Urologe A 1989;28:94-98
Medline11
Berry DA. Statistical methodology in the pharmaceutical sciences. New York: Marcel Dekker, 1990:402-8.
12
Giesbers AAGM ,Bruins JL ,Kramer AEJL ,Jonas U . New methods in the diagnosis of impotence: RigiScan penile tumescence and rigidity monitoring and diagnostic papaverine hydrochloride injection. World J Urol 1987;5:173-176
CrossRef | Web of Science13
Djamilian M ,Stief CG ,Hartmann U ,Jonas U . Predictive value of real-time RigiScan monitoring for the etiology of organogenic impotence. J Urol 1993;149:1269-1271
Web of Science | Medline14
Schramek P ,Waldhauser M . Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction. Br J Clin Pharmacol 1989;28:567-571
Web of Science | Medline15
von Heyden B ,Donatucci CF ,Marshall GA ,Brock GB ,Lue TF . A prostaglandin E1 dose-response study in man. J Urol 1993;150:1825-1828
Web of Science | Medline16
Junemann K-P ,Alken P . Pharmacotherapy of erectile dysfunction: a review. Int J Impot Res 1989;1:71-9317
Linet OI ,Neff LL . Intracavernous prostaglandin E1 in erectile dysfunction. Clin Investig 1994;72:139-149
CrossRef | Medline18
Earle CM ,Keogh EJ ,Ker JK ,Cherry DJ ,Tulloch AGS ,Lord DJ . The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury. Paraplegia 1992;30:273-276
CrossRef | Medline19
Gerber GS ,Levine LA . Pharmacological erection program using prostaglandin E1. J Urol 1991;146:786-789
Web of Science | Medline20
Capetola RJ ,Rosenthale ME ,Dubinsky B ,McGuire JL . Peripheral antialgesics: a review. J Clin Pharmacol 1983;23:545-556
Web of Science | Medline21
Zentgraf M ,Ludwig G ,Ziegler M . How safe is the treatment of impotence with intracavernous autoinjection? Eur Urol 1989;16:165-171
Web of Science | Medline22
Lindsay MB ,Schain DM ,Grambsch P ,Benson RC ,Beard CM ,Kurland LT . The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991;146:1007-1009
Web of Science | Medline23
Amin Z ,Patel U ,Friedman EP ,Vale JA ,Kirby R ,Lees WR . Colour Doppler and duplex ultrasound assessment of Peyronie's disease in impotent men. Br J Radiol 1993;66:398-402
CrossRef | Web of Science | Medline24
Chan JCK ,Levenson S ,Payton TR ,Krane RJ ,Goldstein I . Five to seven year follow-up of patients in a pharmacologic erection program: satisfaction and complications. J Urol 1992;147:Suppl:309A-309A abstract.25
Virag R ,Nollet F ,Greco E ,Paris F . Local tolerance of papaverine-based medications for self intracavernous injections (SICI). J Urol 1994;151:Suppl:456A-456A abstract.26
Kolaja GJ, Kirton KT. Toxicology studies with alprostadil. In: Goldstein I, Lue TF, eds. The role of alprostadil in the diagnosis and treatment of erectile dysfunction. Princeton, N.J.: Excerpta Medica, 1993:40-50.
- Citing Articles (172)
Citing Articles
1
Trustin Domes, Eric Chung, Ling DeYoung, Natalie MacLean, Tariq Al-Shaiji, Gerald Brock. (2011) Clinical Outcomes of Intracavernosal Injection in Postprostatectomy Patients: a Single-Center Experience. Urology
CrossRef2
Annamaria Morelli, Linda Vignozzi, Mario Maggi, Luciano Adorini. (2011) Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:8, 859-866
CrossRef3
F-P Chuang, M Lakin, S-T Wu, T-L Cha, G-H Sun, D K Montague. (2011) Experience with intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: dose considerations. International Journal of Impotence Research 23:4, 146-150
CrossRef4
Ayhan Dirim, Mehmet R. Goren, Levent Peskircioglu. (2011) The Effect of Topical Synthetic Prostaglandin E1 (Misoprostol) on Clitoral Hemodynamics. The Journal of Sexual Medicine 8:3, 800-805
CrossRef5
René Yiou, Patrick Cunin, Alexandre de la Taille, Laurent Salomon, Michele Binhas, Odile Lingombet, Murielle Paul, Claude Abbou. (2011) Sexual Rehabilitation and Penile Pain Associated with Intracavernous Alprostadil after Radical Prostatectomy. The Journal of Sexual Medicine 8:2, 575-582
CrossRef6
Wayland Hsiao, Nelson Bennett, Patricia Guhring, Joseph Narus, John P. Mulhall. (2011) Satisfaction Profiles in Men Using Intracavernosal Injection Therapy. The Journal of Sexual Medicine 8:2, 512-517
CrossRef7
Nicholas J. Silvestri, Christopher H. Gibbons. 2011. Autonomic Dysfunction in Neuromuscular Disorders. , 61-77.
CrossRef8
Walter Pierre Bouman. 2010. Sexual Disorders. , 706-710.
CrossRef9
Mariacristina Vecchio, Sankar D Navaneethan, David W Johnson, Giuseppe Lucisano, Giusi Graziano, Valeria Saglimbene, Marinella Ruospo, Marialuisa Querques, Emmanuele A Jannini, Giovanni FM Strippoli, Mariacristina Vecchio. 2010. Interventions for treating sexual dysfunction in patients with chronic kidney disease. .
CrossRef10
G Yang, C Pan, J Lu. (2010) Prevalence of erectile dysfunction among Chinese men with type 2 diabetes mellitus. International Journal of Impotence Research 22:5, 310-317
CrossRef11
Mathew D. Sorensen, Hunter Wessells. 2010. Management of Erectile Dysfunction. , 134-145.
CrossRef12
Nithya Sukumar, Ansu Basu. (2010) Treatment of erectile dysfunction in the older diabetic patient. Aging Health 6:1, 9-29
CrossRef13
Hartmut Porst, Yoram Vardi, Emre Akkus, Arnold Melman, Nam Cheol Park, Allen D. Seftel, Claudio Teloken, Michael Wyllie. (2010) Standards for Clinical Trials in Male Sexual Dysfunctions. Journal of Sexual Medicine 7:1pt2, 414-444
CrossRef14
Ian Eardley, Craig Donatucci, Jackie Corbin, Amr El-Meliegy, Konstantinos Hatzimouratidis, Kevin McVary, Ricardo Munarriz, Sung Won Lee. (2010) Pharmacotherapy for Erectile Dysfunction. Journal of Sexual Medicine 7:1pt2, 524-540
CrossRef15
Serkan Deveci, John P. Mulhall. 2010. Male Sexual Dysfunction. , 408-413.
CrossRef16
Susan A. Hall, Carol L. Link, Jim C. Hu, Paul W. Eggers, John B. McKinlay. (2009) Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community-based sample. BJU International 104:11, 1680-1688
CrossRef17
Brigitte Esterbauer, Andreas Jungwirth. (2009) Erektile Dysfunktion. Wiener Medizinische Wochenschrift 159:21-22, 529-534
CrossRef18
Eusebio Rubio-Aurioles, Edward D. Kim, Raymond C. Rosen, Harmut Porst, Patrick Burns, Haoyue Zeigler, David G. Wong. (2009) Impact on Erectile Function and Sexual Quality of Life of Couples: A Double-Blind, Randomized, Placebo-Controlled Trial of Tadalafil Taken Once Daily. Journal of Sexual Medicine 6:5, 1314-1323
CrossRef19
Lasantha S. Malavige, Jonathan C. Levy. (2009) Erectile Dysfunction in Diabetes Mellitus. Journal of Sexual Medicine 6:5, 1232-1247
CrossRef20
Mariacristina Vecchio, Sankar D Navaneethan, Giovanni FM Strippoli, Mariacristina Vecchio. 2009. Interventions for treating sexual dysfunction in patients with chronic kidney disease. .
CrossRef21
Michael Rooney, William Pfister, Mary Mahoney, Melissa Nelson, James Yeager, Christopher Steidle. (2009) Long-term, Multicenter Study of the Safety and Efficacy of Topical Alprostadil Cream in Male Patients with Erectile Dysfunction. Journal of Sexual Medicine 6:2, 520-534
CrossRef22
Jeffrey Albaugh, Carol Estwing Ferrans. (2009) Patient-Reported Pain with Initial Intracavernosal Injection. Journal of Sexual Medicine 6:2, 513-519
CrossRef23
Massimo Bocchio, Fiore Pelliccione, Radu Mihalca, Francesco Ciociola, Stefano Necozione, Alessandro Rossi, Felice Francavilla, Sandro Francavilla. (2009) Treatment of erectile dysfunction reduces psychological distress. International Journal of Andrology 32:1, 74-80
CrossRef24
Robert A. Vigersky. 2009. Impotence. , 385-393.
CrossRef25
Péter Riesz, Péter Nyírády, András Rusz. (2009) Férfi merevedési zavarok. Orvosi Hetilap 150:3, 133-135
CrossRef26
W. Wallace Dinsmore, Michael G. Wyllie. (2008) Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU International 102:8, 933-937
CrossRef27
Raanan Tal, John P. Mulhall. (2008) INTRACAVERNOSAL INJECTIONS AND FIBROSIS: MYTH OR REALITY?. BJU International 102:5, 525-526
CrossRef28
Yasusuke Kimoto, Koichi Nagao, Haruaki Sasaki, Ken Marumo, Yoshiatsu Takahashi, Seiji Nishi, Fuminobu Ishikura, Mayumi Futamatsu. (2008) JSSM Guidelines for erectile dysfunction. International Journal of Urology 15:7, 564-576
CrossRef29
Raymond A Costabile, Tony Mammen, Kathleen Hwang. (2008) An overview and expert opinion on the use of alprostadil in the treatment of sexual dysfunction. Expert Opinion on Pharmacotherapy 9:8, 1421-1429
CrossRef30
Gilles Trudel, Vanessa Villeneuve, Anic Anderson, Geneviève Pilon. (2008) Sexual and marital aspects of old age: an update. Sexual and Relationship Therapy 23:2, 161-169
CrossRef31
Atul Luthra, Anoop Misra. (2008) Erectile dysfunction in diabetic males: Plausible mechanisms and management strategies. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2:1, 81-86
CrossRef32
Nadia Brugger, Noel N. Kim, Gian Luca Araldi, Abdulmaged M. Traish, Stephen S. Palmer. (2008) Pharmacological and Functional Characterization of Novel EP and DP Receptor Agonists: DP1 Receptor Mediates Penile Erection in Multiple Species. Journal of Sexual Medicine 5:2, 344-356
CrossRef33
McVary, Kevin T., . (2007) Erectile Dysfunction. New England Journal of Medicine 357:24, 2472-2481
Full Text34
Fernando Branco, Diana D. Cardenas, Jelena N. Svircev. (2007) Spinal Cord Injury: A Comprehensive Review. Physical Medicine and Rehabilitation Clinics of North America 18:4, 651-679
CrossRef35
P. J. R. Shah, W. Dinsmore, R. A. Oakes, Geoff Hackett. (2007) Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. Current Medical Research and Opinion 23:10, 2577-2583
CrossRef36
William O Brant, Gerald B Brock, Tom F Lue, Ronald G Gerridzen, Anthony J Bella. (2007) Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. Aging Health 3:4, 527-542
CrossRef37
David M Fenig, Andrew McCullough. (2007) Sildenafil in the treatment of erectile dysfunction. Aging Health 3:3, 295-303
CrossRef38
Benjamin Alexandre, Antoine Lemaire, Pierre Desvaux, Edouard Amar. (2007) Intracavernous Injections of Prostaglandin E1 for Erectile Dysfunction: Patient Satisfaction and Quality of Sex Life on Long-Term Treatment. The Journal of Sexual Medicine 4:2, 426-431
CrossRef39
Annette M. Shadiack, Shubh D. Sharma, Dennis C. Earle, Carl Spana, Trevor J. Hallam. (2006) A role for melanocortin agonists in treating male and female sexual dysfunction. Drug Discovery Today: Therapeutic Strategies 3:4, 605-611
CrossRef40
L. Dean Knoll. (2006) The role of penile implantation surgery in the era of effective pharmacotherapy for the management of erectile dysfunction. Current Sexual Health Reports 3:3, 100-102
CrossRef41
K Nandipati, R Raina, A Agarwal, C D Zippe. (2006) Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. International Journal of Impotence Research 18:5, 446-451
CrossRef42
Petros Perimenis, Konstantinos Giannitsas. (2006) Existing and future pharmacotherapy for erectile dysfunction. Expert Opinion on Therapeutic Patents 16:9, 1215-1222
CrossRef43
Harin Padma-Nathan, James L. Yeager. (2006) An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology 68:2, 386-391
CrossRef44
Giuseppe Cirino, Ferdinando Fusco, Ciro Imbimbo, Vincenzo Mirone. (2006) Pharmacology of erectile dysfunction in man. Pharmacology & Therapeutics 111:2, 400-423
CrossRef45
Massimo Bocchio, Piero Scarpelli, Stefano Necozione, Fiore Pelliccione, Carlo Spartera, Felice Francavilla, Sandro Francavilla. (2006) Penile duplex pharmaco-ultrasonography of cavernous arteries in men with erectile dysfunction and generalized atherosclerosis. International Journal of Andrology 29:4, 496-501
CrossRef46
Eric Wespes, Edouard Amar, Dimitrios Hatzichristou, Kosta Hatzimouratidis, Francesco Montorsi, John Pryor, Yoram Vardi. (2006) EAU Guidelines on Erectile Dysfunction: An Update. European Urology 49:5, 806-815
CrossRef47
Rany Shamloul, Ihab Kamel. (2006) Early Treatment of Cavernositis Resulted in Erectile Function Preservation.. The Journal of Sexual Medicine 3:2, 320-322
CrossRef48
Christopher H. Gibbons, Roy Freeman. (2006) Treatment options for autonomic neuropathies. Current Treatment Options in Neurology 8:2, 119-132
CrossRef49
Arshag D. Mooradian, Stanley G. Korenman. (2006) Management of the Cardinal Features of Andropause. American Journal of Therapeutics 13:2, 145-160
CrossRef50
Onder Yaman, Murat Akand, Alptekin Gursoy, Murat Faik Erdogan, Kadri Anafarta. (2006) The Effect of Diabetes Mellitus Treatment and Good Glycemic Control on the Erectile Function in Men with Diabetes Mellitus-Induced Erectile Dysfunction: A Pilot Study. The Journal of Sexual Medicine 3:2, 344-348
CrossRef51
2006. Prostaglandins. , 2955-2964.
CrossRef52
Culley C. Carson, J. Slade Hubbard, Eric Wallen. (2005) Erectile dysfunction and treatment of carcinoma of the prostate. Current Urology Reports 6:6, 461-469
CrossRef53
(2005) Simultaneous Determination of Prostaglandin E 1 and Prostaglandin E 1 Ethyl Ester in Hairless Mouse Skin Homogenate by High-Performance Liquid Chromatography. Journal of Korean Pharmaceutical Sciences 35:5, 375-381
CrossRef54
Nancy F. Crum, Kari J. Furtek, Patrick E. Olson, Christopher L. Amling, Mark R. Wallace. (2005) A Review of Hypogonadism and Erectile Dysfunction Among HIV-Infected Men During the Pre- and Post-HAART Eras: Diagnosis, Pathogenesis, and Management. AIDS Patient Care and STDs 19:10, 655-671
CrossRef55
Nancy F. Crum, Kari J. Furtek, Patrick E. Olson, Christopher L. Amling, Mark R. Wallace. (2005) A Review of Hypogonadism and Erectile Dysfunction Among HIV-Infected Men During the Pre- and Post-HAART Eras: Diagnosis, Pathogenesis, and Management. AIDS Patient Care and STDs 19:10, 869-885
CrossRef56
Lizette J. Smith. (2005) Erectile dysfunction in the aging male. Current Sexual Health Reports 2:1, 13-16
CrossRef57
K.-P. Jünemann, S. Caßens, H. Lippert, M. Burkart. (2005) Qualitätssicherung in der urologischen Praxis. Der Urologe 44:7, 785-793
CrossRef58
Jean H. Lewis, Raymond Rosen, Irwin Goldstein. (2004) Erectile Dysfunction in Primary Care. The Nurse Practitioner 29:12, 42-55
CrossRef59
Rabih A. Hijazi, Marion Betancourt-Albrecht, Glenn R. Cunningham. (2004) Gonadal and erectile dysfunction in diabetics. Medical Clinics of North America 88:4, 933-945
CrossRef60
Riccardo Urciuoli, Teresa Anna Cantisani, Marzia Carlini, Marta Giuglietti, Fabio Massimo Botti, Riccardo Urciuoli. 2004. Prostaglandin E1 for treatment of erectile dysfunction. .
CrossRef61
Hossein Sadeghi-Nejad, Vikram Dogra, Allen D Seftel, Mamdouh A Mohamed. (2004) Priapism. Radiologic Clinics of North America 42:2, 427-443
CrossRef62
Rupesh Raina, Milton M Lakin, Ashok Agarwal, Sandra Ausmundson, Drogo K Montague, Craig D Zippe. (2004) Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy. Urology 63:3, 532-537
CrossRef63
Edgardo Becher. (2004) Topical alprostadil cream for the treatment of erectile dysfunction. Expert Opinion on Pharmacotherapy 5:3, 623-632
CrossRef64
Michael H. Cummings. 2004. Erectile Dysfunction in Diabetes Mellitus. .
CrossRef65
Michael Edmonds. 2004. Autonomic Neuropathy. .
CrossRef66
M. FUJISAWA, K. SAWADA. (2004) CLINICAL EFFICACY AND SAFETY OF SILDENAFIL IN ELDERLY PATIENTS WITH ERECTILE DYSFUNCTION. Systems Biology in Reproductive Medicine 50:4, 255-260
CrossRef67
Jean H. Lewis, Raymond Rosen, Irwin Goldstein. (2003) Erectile Dysfunction. AJN, American Journal of Nursing 103:10, 48-57
CrossRef68
Garrett H Lischer, Ajay Nehra. (2003) Therapies for neurologic erectile dysfunction. Expert Review of Neurotherapeutics 3:5, 641-648
CrossRef69
JOHN P. MULHALL. (2003) Deciphering Erectile Dysfunction Drug Trials. The Journal of Urology 170:2, 353-358
CrossRef70
RAYMOND A. COSTABILE. (2003) Optimizing Treatment for Diabetes Mellitus Induced Erectile Dysfunction. The Journal of Urology 170:2, S35-S39
CrossRef71
ATUL RAJPURKAR, CHIRPRIYA B. DHABUWALA. (2003) Comparison of Satisfaction Rates and Erectile Function in Patients Treated with Sildenafil, Intracavernous Prostaglandin E1 and Penile Implant Surgery for Erectile Dysfunction in Urology Practice. The Journal of Urology 170:1, 159-163
CrossRef72
PAOLO GONTERO, FRANCESCO FONTANA, ANDREA BAGNASACCO, MASSIMILIANO PANELLA, ERVIN KOCJANCIC, GIULIANO PRETTI, BRUNO FREA. (2003) Is There an Optimal Time for Intracavernous Prostaglandin E1 Rehabilitation Following Nonnerve Sparing Radical Prostatectomy? Results From a Hemodynamic Prospective Study. The Journal of Urology 169:6, 2166-2169
CrossRef73
Liming Jin, A Elizabeth Linder, Thomas M Mills, R Clinton Webb. (2003) Inhibition of the tonic contraction in the treatment of erectile dysfunction. Expert Opinion on Therapeutic Targets 7:2, 265-276
CrossRef74
Ridwan Shabsigh, Aristotelis G. Anastasiadis. (2003) Erectile Dysfunction. Annual Review of Medicine 54:1, 153-168
CrossRef75
David W. Jenkins, Patrick P.A. Humphrey, Robert A. Coleman. 2003. Agents Acting on Prostanoid Receptors. .
CrossRef76
Hossein Sadeghi-Nejad, Allen D. Seftel. (2002) The etiology, diagnosis, and treatment of priapism: Review of the American Foundation for Urologic Disease Consensus Panel report. Current Urology Reports 3:6, 492-498
CrossRef77
John P. Pryor. (2002) Pharmacotherapy of erectile dysfunction. Sexual and Relationship Therapy 17:4, 389-400
CrossRef78
Arnold Melman, George J. Christ. (2002) The Hemodynamics of Erection and the Pharmacotherapies of Erectile Dysfunction. Heart Disease 4:4, 252-264
CrossRef79
Aristotelis G Anastasiadis, Mohamed A Ghafar, Ridwan Shabsigh, Martin Burchardt. (2002) Economic aspects of medical erectile dysfunction therapies. Expert Opinion on Pharmacotherapy 3:3, 257-263
CrossRef80
Michelle S. Gittler, William O. McKinley, Steven A. Stiens, Suzanne L. Groah, Steven C. Kirshblum. (2002) 3. Rehabilitation outcomes. Archives of Physical Medicine and Rehabilitation 83:3, S65-S71
CrossRef81
R Urciuoli, TA Cantisani, M Carlini, M Giuglietti, FM Botti. 2002. Prostaglandin E1 for treatment of erectile dysfunction. .
CrossRef82
Mark A Moyad. (2002) The placebo effect and randomized trials: analysis of conventional medicine. Urologic Clinics of North America 29:1, 125-133
CrossRef83
Irwin Goldstein, Tom F. Lue, Harin Padma-Nathan, Raymond C. Rosen, William D. Steers, Pierre A. Wicker. (2002) Oral sildenafil in the treatment of erectile dysfunction. The Journal of Urology 167:2, 1197-1203
CrossRef84
Peter A. Milligan, Scott F. Marshall, Mats O. Karlsson. (2002) A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. British Journal of Clinical Pharmacology 53, 45S-52S
CrossRef85
Culley C. Carson. (2002) Editorial comment. The Journal of Urology 167:2, 1204
CrossRef86
M. Fujisawa, K. Sawada, H. Okada, S. Arakawa, S. Saito, S. Kamidono. (2002) EVALUATION OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS TREATED FOR ERECTILE DYSFUNCTION WITH VIAGRA (SILDENAFIL CITRATE) USING SF-36 SCORE. Systems Biology in Reproductive Medicine 48:1, 15-21
CrossRef87
John A. Thomas. (2002) Pharmacological Aspects of Erectile Dysfunction. The Japanese Journal of Pharmacology 89:2, 101-112
CrossRef88
M. A. Khan, M. Raistrick, D. P. Mikhailidis, R. J. Morgan. (2002) MUSE™: Clinical Experience. Current Medical Research and Opinion 18:2, 64-67
CrossRef89
Ajay Nehra. (2001) Intracavernosal therapy: When oral agents fail. Current Urology Reports 2:6, 468-472
CrossRef90
Tom F. Lue. (2001) Neurogenic erectile dysfunction. Clinical Autonomic Research 11:5, 285-294
CrossRef91
Elliot Fagelman, Andrew Fagelman, Ridwan Shabsigh. (2001) Efficacy, safety, and use of sildenafil in urologic practice. Urology 57:6, 1141-1144
CrossRef92
Karl-Erik Andersson. (2001) PHARMACOLOGY OF ERECTILE FUNCTION AND DYSFUNCTION. Urologic Clinics of North America 28:2, 233-248
CrossRef93
Stephen E. Pautler, Gerald B. Brock. (2001) PRIAPISM. Urologic Clinics of North America 28:2, 391-404
CrossRef94
Ajay Nehra, Robert B. Moreland. (2001) NEUROLOGIC ERECTILE DYSFUNCTION. Urologic Clinics of North America 28:2, 289-308
CrossRef95
JUZA CHEN, NICOLA J. MABJEESH, ALEXANDER GREENSTEIN, ANDREI NADU, HAIM MATZKIN. (2001) CLINICAL EFFICACY OF SILDENAFIL IN PATIENTS ON CHRONIC DIALYSIS. The Journal of Urology819-821
CrossRef96
JUZA CHEN, NICOLA J. MABJEESH, ALEXANDER GREENSTEIN, ANDREI NADU, HAIM MATZKIN. (2001) CLINICAL EFFICACY OF SILDENAFIL IN PATIENTS ON CHRONIC DIALYSIS. The Journal of Urology 165:3, 819-821
CrossRef97
Gerald Brock, Lei Mai Tu, Otto I Linet. (2001) Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Urology 57:3, 536-541
CrossRef98
G. Wagner, F. Montorsi, S. Auerbach, M. Collins. (2001) Sildenafil Citrate (VIAGRA(R)) Improves Erectile Function in Elderly Patients With Erectile Dysfunction: A Subgroup Analysis. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56:2, M113-M119
CrossRef99
Dinko Vitezic. (2001) A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction. Drug Safety 24:4, 255-265
CrossRef100
Culley C. Carson. (2000) Oral and injectable medications for the treatment of erectile dysfunction. Current Urology Reports 1:4, 307-312
CrossRef101
Trinity J Bivalacqua, Hunter C Champion, Wayne J.G Hellstrom, Philip J Kadowitz. (2000) Pharmacotherapy for erectile dysfunction. Trends in Pharmacological Sciences 21:12, 484-489
CrossRef102
Jack Baniel, Solomon Israilov, Dov Engelstein, Joseph Shmueli, Ephraim Segenreich, Pinhas M Livne. (2000) Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs. Urology 56:4, 647-652
CrossRef103
J.H. Mydlo, M.A. Volpe, R.J. Macchia. (2000) Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction. BJU International 86:4, 469-473
CrossRef104
David L. Rowland, Arthur L. Burnett. (2000) Pharmacotherapy in the treatment of male sexual dysfunction. Journal of Sex Research 37:3, 226-243
CrossRef105
Jeremy P.W. Heaton. (2000) Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neuroscience & Biobehavioral Reviews 24:5, 561-569
CrossRef106
Raymond C Rosen, Benjamin D Sachs. (2000) Central mechanisms in the control of penile erection: current theory and research. Neuroscience & Biobehavioral Reviews 24:5, 503-505
CrossRef107
PEJMAN COHAN, STANLEY G. KORENMAN. (2000) Progress in Erectile Dysfunction and Hormone Function. Journal of Anti-Aging Medicine 3:2, 169-175
CrossRef108
Robert Taylor Segraves. (2000) New treatment for erectile dysfunction. Current Psychiatry Reports 2:3, 206-210
CrossRef109
R Shabsigh, H Padma-Nathan, M Gittleman, J McMurray, J Kaufman, I Goldstein. (2000) Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 55:4, 477-480
CrossRef110
Andy Levy, Tessa Crowley, Clive Gingell. (2000) Non-surgical management of erectile dysfunction. Clinical Endocrinology 52:3, 253-260
CrossRef111
YORAM VARDI, ELLIOT SPRECHER, ILAN GRUENWALD. (2000) LOGISTIC REGRESSION AND SURVIVAL ANALYSIS OF 450 IMPOTENT PATIENTS TREATED WITH INJECTION THERAPY: LONG-TERM DROPOUT PARAMETERS. The Journal of Urology 163:2, 467-470
CrossRef112
YORAM VARDI, ELLIOT SPRECHER, ILAN GRUENWALD. (2000) LOGISTIC REGRESSION AND SURVIVAL ANALYSIS OF 450 IMPOTENT PATIENTS TREATED WITH INJECTION THERAPY:. The Journal of Urology467
CrossRef113
KURT LEHMANN, REMY EICHLISBERGER, THOMAS C. GASSER. (2000) LACK OF DIAGNOSTIC TOOLS TO PROVE ERECTILE DYSFUNCTION: CONSEQUENCES FOR REIMBURSEMENT?. The Journal of Urology 163:1, 91-94
CrossRef114
KURT LEHMANN, REMY EICHLISBERGER, THOMAS C. GASSER. (2000) LACK OF DIAGNOSTIC TOOLS TO PROVE ERECTILE DYSFUNCTION:. The Journal of Urology91
CrossRef115
Masood A. Khan, Dimitri P. Mikhailidis, Robert J. Morgan. (2000) Sildenafil: a Urologist's View. Current Medical Research and Opinion 16:s1, s48-s58
CrossRef116
R Shabsigh, H Padma-Nathan, M Gittleman, J McMurray, J Kaufman, I Goldstein. (2000) Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional ACTIS: a comparative, randomized, crossover, multicenter study. Urology 55:1, 109-113
CrossRef117
ANA ESCRIG, RAQUEL MARIN, MANUEL MAS. (1999) REPEATED PGE1 TREATMENT ENHANCES NITRIC OXIDE AND ERECTION RESPONSES TO NERVE STIMULATION IN THE RAT PENIS BY UPREGULATING CONSTITUTIVE NOS ISOFORMS. The Journal of Urology 162:6, 2205-2210
CrossRef118
SUSAN D. MATHIAS, MICHAEL P. O’LEARY, JAMES M. HENNING, DAVID J. PASTA, SUSAN FROMM, RAYMOND C. ROSEN. (1999) A COMPARISON OF PATIENT AND PARTNER RESPONSES TO A BRIEF SEXUAL FUNCTION QUESTIONNAIRE. The Journal of Urology 162:6, 1999-2002
CrossRef119
CHRIS G. McMAHON, RAMIN SAMALI, HELEN JOHNSON. (1999) TREATMENT OF INTRACORPOREAL INJECTION NONRESPONSE WITH SILDENAFIL ALONE OR IN COMBINATION WITH TRIPLE AGENT INTRACORPOREAL INJECTION THERAPY. The Journal of Urology 162:6, 1992-1998
CrossRef120
Emmanuele A. Jannini, Emiliano Screponi, Eleonora Carosa, Mario Pepe, Francesco Lo Giudice, Francesco Trimarchi, Salvatore Benvenga. (1999) Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. International Journal of Andrology 22:6, 385-392
CrossRef121
JC Gingell, R Lockyer. (1999) Emerging pharmacological therapies for erectile dysfunction. Expert Opinion on Therapeutic Patents 9:12, 1689-1696
CrossRef122
Jon Cartledge, Ian Eardley. (1999) Sildenafil. Expert Opinion on Pharmacotherapy 1:1, 137-147
CrossRef123
Fran E. Kaiser. (1999) ERECTILE DYSFUNCTION IN THE AGING MAN. Medical Clinics of North America 83:5, 1267-1278
CrossRef124
A Nehra, D M Barrett, R B Moreland. (1999) Pharmacotherapeutic advances in the treatment of erectile dysfunction.. Mayo Clinic Proceedings 74:7, 709-721
CrossRef125
Raymond A Costabile. (1999) Alprostadil for the treatment of erectile dysfunction. Expert Opinion on Investigational Drugs 8:6, 877-884
CrossRef126
Shokeir, Alserafi, Mutabagani. (1999) Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU International 83:7, 812-815
CrossRef127
Stanley E Althof, Eric W Corty, Stephen B Levine, Frederic Levine, Arthur L Burnett, Kevin McVary, Vera Stecher, Allen D Seftel. (1999) EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 53:4, 793-799
CrossRef128
Werner J Reiter, Armin Pycha, Georg Schatzl, Alexej Pokorny, Doris M Gruber, Johannes C Huber, Michael Marberger. (1999) Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology 53:3, 590-594
CrossRef129
Steven A. Kaplan, Rodolfo B. Reis, Ira J. Kohn, Edward F. Ikeguchi, Eliahu Laor, Alexis E. Te, Antonio C.P. Martins. (1999) Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 53:3, 481-486
CrossRef130
Stephen B. Levine. (1999) Caution recommeaded. Journal of Sex & Marital Therapy 25:1, 2-5
CrossRef131
George R. Parkerson, Richard J. Willke, Ron D. Hays. (1999) An International Comparison of the Reliability and Responsiveness of the Duke Health Profile for Measuring Health-Related Quality of Life of Patients Treated With Alprostadil for Erectile Dysfunction. Medical Care 37:1, 56-67
CrossRef132
PAT F. FULGHAM, JAMES S. COCHRAN, JOHN L. DENMAN, BRIAN A. FEAGINS, MICHAEL B. GROSS, KEITH T. KADESKY, MELVIN C. KADESKY, ANGELA R. CLARK, CLAUS G. ROEHRBORN. (1998) DISAPPOINTING INITIAL RESULTS WITH TRANSURETHRAL ALPROSTADIL FOR ERECTILE DYSFUNCTION IN A UROLOGY PRACTICE SETTING. The Journal of Urology 160:6, 2041-2046
CrossRef133
MAQSOOD UL-HASAN, AHMED EL-SAKKA, CELESTE LEE, TIEN-SZE YEN, RAJVIR DAHIYA, TOM LUE. (1998) EXPRESSION OF TGF-beta-1 mRNA AND ULTRASTRUCTURAL ALTERATIONS IN PHARMACOLOGICALLY INDUCED PROLONGED PENILE ERECTION IN A CANINE MODEL. The Journal of Urology2263-2266
CrossRef134
MAQSOOD UL-HASAN, AHMED EL-SAKKA, CELESTE LEE, TIEN-SZE YEN, RAJVIR DAHIYA, TOM LUE. (1998) EXPRESSION OF TGF-beta-1 mRNA AND ULTRASTRUCTURAL ALTERATIONS IN PHARMACOLOGICALLY INDUCED PROLONGED PENILE ERECTION IN A CANINE MODEL. The Journal of Urology 160:6, 2263-2266
CrossRef135
Marvin M. Goldenberg. (1998) Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clinical Therapeutics 20:6, 1033-1048
CrossRef136
Steven A Kaplan, Rodolfo B Reis, Ira J Kohn, Ridwan Shabsigh, Alexis E Te. (1998) Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urology 52:5, 739-743
CrossRef137
K.Steven Ansong, Carol Lewis, Paul Jenkins, Joseph Bell. (1998) Help-seeking decisions among men with impotence. Urology 52:5, 834-837
CrossRef138
Ira D. Sharlip. (1998) EVALUATION AND NONSURGICAL MANAGEMENT OF ERECTILE DYSFUNCTION. Urologic Clinics of North America 25:4, 647-659
CrossRef139
Oakley, Moore. (1998) Vacuum devices in erectile dysfunction: indications and efficacy. BJU International 82:5, 673-681
CrossRef140
SL Hyer, K Duckworth, C Jones. (1998) Managing erectile disorders in diabetes: The one-stop andrology clinic. Practical Diabetes International 15:8, 225-226
CrossRef141
(1998) The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. BJU International 82:4, 538-543
CrossRef142
David J. Handelsman, Peter Y. Liu. (1998) Androgen therapy in chronic renal failure. Baillière's Clinical Endocrinology and Metabolism 12:3, 485-500
CrossRef143
Glyn Hudson-allez. (1998) The interface between psychogenic and organic difficulties in men with erectile dysfunction. Sexual and Marital Therapy 13:3, 285-293
CrossRef144
R. T. Segraves, K. B. Segraves. (1998) Pharmacotherapy for sexual disorders: Advantages and pitfalls. Sexual and Marital Therapy 13:3, 295-309
CrossRef145
Williams, Abbou, Amar, Desvaux, Flam, Lycklama a Nijeholt, Lynch, Morgan, MUller, Porst, Pryor, Ryan, Witzsch, Hall, Place, Spivack, Gesundheit on behalf of the Muse St. (1998) Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. BJU International 81:6, 889-894
CrossRef146
J. Buvat, E. Amar, O. Cambau, P. Desvaux, A. Gout, A. Leriche. (1998) Comparaison randomisee en double insu d’injections intracaverneuses d’alprostadil-alfadex et de chlorhydrate de moxisylyte dans 156 cas de dysfonction erectile chronique. Andrologie 8:2, 204-212
CrossRef147
Bettocchi, Ashford, Pryor, Ralph. (1998) Priapism after transurethral alprostadil. BJU International 81:6, 926-926
CrossRef148
Utiger, Robert D., . (1998) A Pill for Impotence. New England Journal of Medicine 338:20, 1458-1459
Full Text149
Goldstein, Irwin, Lue, Tom F., Padma-Nathan, Harin, Rosen, Raymond C., Steers, William D., Wicker, Pierre A., . (1998) Oral Sildenafil in the Treatment of Erectile Dysfunction. New England Journal of Medicine 338:20, 1397-1404
Full Text150
CRAIG A. PETERSON, ALAN H. BENNETT, WAYNE J.G. HELLSTROM, FRAN E. KAISER, JOHN E. MORLEY, KERRY J. NEMO, HARIN PADMA-NATHAN, VIRGIL A. PLACE, J. JOSEPH PRENDERGAST, PETER Y. TAM, EMIL A. TANAGHO, LESLIE K. TODD, JOHN C. VARADY, NEIL GESUNDHEIT. (1998) ERECTILE RESPONSE TO TRANSURETHRAL ALPROSTADIL, PRAZOSIN AND ALPROSTADIL-PRAZOSIN COMBINATIONS. The Journal of Urology 159:5, 1523-1528
CrossRef151
E.M. Smith, I.C.V. Netto, K.H. Gladden, T.K. Chaudhuri, S. Fink, P. Kolm. (1998) Role of radionuclide phallogram in therapeutic decision-making for erectile dysfunction. Urology 51:5, 175-178
CrossRef152
WAYNE J.G. HELLSTROM, RUN WANG, CRAIG A. PETERSON, JOHN C. VARADY, NEIL GESUNDHEIT, SURESH C. SIKKA. (1998) EFFECTS OF ALPROSTADIL AND PRAZOSIN ON MOTILITY, VIABILITY AND MEMBRANE INTEGRITY OF HUMAN SPERM. The Journal of Urology 159:5, 1559-1562
CrossRef153
Gingell. (1998) New developments in self-injection therapy for erectile dysfunction. BJU International 81:4, 599-603
CrossRef154
Dinsmore, Alderdice. (1998) Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. BJU International 81:3, 437-440
CrossRef155
P. Steadman, S. J. Cope, J. P. Watson. (1998) Erectile failure in a man with schizophrenia and diabetes mellitus successfully treated by intracavernosal injection. Sexual and Marital Therapy 13:1, 91-93
CrossRef156
W.P. De Silva. 1998. Sexual Problems: Dysfunction. , 603-621.
CrossRef157
Jacques Buvat, Pierre Costa, Dominique Morlier, Brigitte Lecocq, Barbara Stegmann, Detlef Albrecht. (1998) DOUBLE-BLIND MULTICENTER STUDY COMPARING ALPROSTADIL α-CYCLODEXTRIN WITH MOXISYLYTE CHLORHYDRATE IN PATIENTS WITH CHRONIC ERECTILE DYSFUNCTION. The Journal of Urology 159:1, 116-119
CrossRef158
Raouf M. Seyam, Louis R. Bégin, Le Mai Tu, Stéphane B. Dion, Scott L. Merlin, Gerald B. Brock. (1997) Evaluation of a no-needle penile injector: a preliminary study evaluating tissue penetration and its hemodynamic consequences in the rat. Urology 50:6, 994-998
CrossRef159
John P. Mulhall, Meir Daller, Abdulmaged M. Traish, Sandeep Gupta, Kwangsung Park, Pedram Salimpour, Terry R. Payton, Robert J. Krane, Irwin Goldstein. (1997) INTRACAVERNOSAL FORSKOLIN: ROLE IN MANAGEMENT OF VASCULOGENIC IMPOTENCE RESISTANT TO STANDARD 3-AGENT PHARMACOTHERAPY. The Journal of Urology 158:5, 1752-1758
CrossRef160
Francesco Montorsi, Giorgio Guazzoni Luigi, Luigi Ferini Strambi, Luigi F. Da Pozzo, Luciano Nava, Luigi Barbieri, Patrizio Rigatti, Giuliano Pizzini, Alberto Miani. (1997) RECOVERY OF SPONTANEOUS ERECTILE FUNCTION AFTER NERVE-SPARING RADICAL RETROPUBIC PROSTATECTOMY WITH AND WITHOUT EARLY INTRACAVERNOUS INJECTIONS OF ALPROSTADIL: RESULTS OF A PROSPECTIVE, RANDOMIZED TRIAL. The Journal of Urology 158:4, 1408-1410
CrossRef161
Francesco Montorsi, Giorgio Guazzoni Luigi, Luigi Ferini Strambi, Luigi F. Da Pozzo, Luciano Nava, Luigi Barbieri, Patrizio Rigatti, Giuliano Pizzini, Alberto Miani. (1997) RECOVERY OF SPONTANEOUS ERECTILE FUNCTION AFTER NERVE-SPARING RADICAL RETROPUBIC PROSTATECTOMY WITH AND WITHOUT EARLY INTRACAVERNOUS INJECTIONS OF ALPROSTADIL. The Journal of Urology1408-1410
CrossRef162
Richard J. Willke, Henry A. Glick, Thomas J. McCarron, M. Haim Erder, Stanley E. Althof, Otto I. Linet. (1997) Quality of Life Effects of Alprostadil Therapy for Erectile Dysfunction. The Journal of Urology 157:6, 2124-2128
CrossRef163
Henry A. Glick, Thomas J. McCarron, Stanley E. Althof, Eric W. Corty, Richard J. Willke. (1997) Construction of scales for the Center for Marital and Sexual Health (CMASH) sexual functioning questionnaire. Journal of Sex & Marital Therapy 23:2, 103-117
CrossRef164
Ruchira Gupta, Jill Kirschen, Robert C. Barrow, Jean Francois Eid. (1997) Predictors of Success and Risk Factors for Attrition in the Use of Intracavernous Injection. The Journal of Urology 157:5, 1681-1686
CrossRef165
Ruchira Gupta, Jill Kirschen, Robert C. II Barrow, Jean Francois Eid. (1997) Predictors of Success and Risk Factors for Attrition in the Use of Intracavernous Injection. The Journal of Urology1681-1686
CrossRef166
Arno W.F.T. Toorians, Erik J. Giltay, Ab J.M. Donker, Louis J. G. Gooren. (1997) Sexual Functioning in Chronic Renal Failure. Seminars in Dialysis 10:3, 176-181
CrossRef167
Karl-Erik Andersson, Christian G. Stief. (1997) Neurotransmission and the contraction and relaxation of penile erectile tissues. World Journal of Urology 15:1, 14-20
CrossRef168
Padma-Nathan, Harin, Hellstrom, Wayne J.G., Kaiser, Fran E., Labasky, Richard F., Lue, Tom F., Nolten, Wolfram E., Norwood, Paul C., Peterson, Craig A., Shabsigh, Ridwan, Tam, Peter Y., Place, Virgil A., Gesundheit, Neil, Cowley, Christy, Nemo, Kerry J.Spivack, Alfred P., Stephens, Darby E., Todd, Leslie K., . (1997) Treatment of Men with Erectile Dysfunction with Transurethral Alprostadil. New England Journal of Medicine 336:1, 1-7
Full Text169
S Vaidyanathan, K R Krishnan. (1996) Myocardial infarction associated with intra-cavernosal administration of alprostadil in a patient with spinal cord injury and paraplegia. Spinal Cord 34:12, 754-755
CrossRef170
Wayne J.G. Hellstrom, Alan H. Bennett, Neil Gesundheit, Fran E. Kaiser, Tom F. Lue, Harin Padma-Nathan, Craig A. Peterson, Peter Y. Tam, Leslie K. Todd, John C. Varady, Virgil A. Place. (1996) A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology 48:6, 851-856
CrossRef171
A. AVERSA, M. ROCCHIETTI-MARCH, M. CAPRIO, D. GIANNINI, A. ISIDORI, A. FABBRI. (1996) Anxiety-induced failure in erectile response to intracorporeal prostaglandin-E 1 in non-organic male impotence: a new diagnostic approach. International Journal of Andrology 19:5, 307-313
CrossRef172
Lipshultz, Larry I., . (1996) Injection Therapy for Erectile Dysfunction. New England Journal of Medicine 334:14, 913-914
Full Text
